StockNews.AI
RVNC
StockNews.AI
222 days

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

1. Revance is facing a class action lawsuit for misleading statements. 2. Allegations include breach of agreement with Teoxane and increased litigation risks. 3. Shareholders are urged to register by March 4, 2025 for monitoring. 4. The suit could adversely affect Revance's stock performance and reputation. 5. The law firm aims to protect rights of investors and recover losses.

4m saved
Insight
Article

FAQ

Why Bearish?

Legal troubles can cause stock price declines, as seen in similar cases previously.

How important is it?

The class action lawsuit and its implications on Revance's business practices are likely to impact stock value.

Why Short Term?

The deadline for shareholders will create immediate market concerns affecting stock price quickly.

Related Companies

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).

Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4

CLASS PERIOD:

February 29, 2024 to December 6, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE:

March 4, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 4, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm

Related News